University-Industry Engagement Week

Danaher Corp. partners with Penn in bid to boost availability of cell therapies


By David Schwartz
Published: March 14th, 2023

Danaher Corporation, a global conglomerate focused on science and technology innovation, has entered a strategic partnership with the University of Pennsylvania (Penn) that aims to improve the ability to scale up cell therapies and make them more widely accessible. The multi-year partnership is designed to develop new technologies that will improve the consistency of clinical outcomes and overcome manufacturing bottlenecks in the delivery of engineered cell products.

There are currently six CAR T cell therapies approved by the U.S. Food and Drug Administration and at least 560 programs in ongoing clinical trials, reflecting the huge potential the biopharma industry sees for new cell therapies therapies. However, up to now the impact of cell therapies has been limited by an inability to scale manufacturing in a cost- and time-effective way.

“Our understanding of science is evolving faster than ever, but to efficiently translate these discoveries into potentially life-changing therapies we need an equivalent acceleration in manufacturing innovation, said Vanessa Almendro, Danaher’s VP for Science and Technology Innovation. “We are delighted to be partnering with the CAR T pioneers at Penn and believe that combining our expertise in science and technology will help bring the next generation of cell therapies to patients faster.”

Penn Professor of Immunotherapy Carl H. June, MD, added: “We look forward to working together to address some of the current challenges of the complex manufacturing process for CAR T cell therapy and to maximize the impact of these cellular immunotherapies for more patients in need.”

The multi-year program with Penn, referred to as a “Beacon” by the company, is a part of the Danaher Beacons program, which funds pioneering scientific research carried out in academic settings. The Beacon program’s focus areas include genomic medicines, precision diagnostics, next generation biomanufacturing, human systems, and data sciences.

Source: Danaher

Posted under: University-Industry Engagement Week